Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.69 +5.8%	$10.80	$3.98 ▼ $12.83	$1.68B	1.92	1.72 million shs	4.65 million shs
ATYR aTyr Pharma	$5.34 +2.3%	$5.28	$1.67 ▼ $7.29	$464.60M	0.94	5.92 million shs	3.52 million shs
IMCR Immunocore	$32.10 -1.2%	$34.30	$23.15 ▼ $39.33	$1.63B	0.77	262,398 shs	584,505 shs
SRPT Sarepta Therapeutics	$16.26 -2.9%	$22.54	$10.41 ▼ $145.00	$1.65B	0.46	21.53 million shs	13.20 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+5.79%	+11.97%	-0.43%	+26.11%	+153.58%
ATYR aTyr Pharma	+2.30%	+8.10%	+0.75%	+59.88%	+185.56%
IMCR Immunocore	-1.23%	-4.18%	-0.96%	+8.26%	-15.68%
SRPT Sarepta Therapeutics	-2.93%	-2.93%	-6.12%	-55.48%	-88.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8128 of 5 stars	1.4	2.0	4.2	1.8	2.5	0.6
ATYR aTyr Pharma	2.4305 of 5 stars	3.6	1.0	0.0	3.2	1.7	0.6
IMCR Immunocore	1.778 of 5 stars	3.3	1.0	0.0	2.2	2.5	0.0
SRPT Sarepta Therapeutics	4.6221 of 5 stars	4.1	2.0	4.2	3.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	5.86% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	278.28% Upside
IMCR Immunocore	2.55	Moderate Buy	$58.89	83.45% Upside
SRPT Sarepta Therapeutics	2.10	Hold	$49.12	202.09% Upside

Current Analyst Ratings Breakdown

Latest ATYR, IMCR, ADPT, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00
7/29/2025	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$15.00
7/29/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell
7/29/2025	SRPT Sarepta Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
7/29/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$30.00 ➝ $37.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$205.22M	8.65	N/A	N/A	$1.37 per share	8.53
ATYR aTyr Pharma	$230K	2,066.35	N/A	N/A	$0.83 per share	6.43
IMCR Immunocore	$310.20M	5.20	N/A	N/A	$7.20 per share	4.46
SRPT Sarepta Therapeutics	$1.90B	0.84	$2.36 per share	6.88	$15.99 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-59.01%	-22.61%	N/A
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/7/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.49	N/A	-11.12%	-14.88%	-5.12%	N/A

Latest ATYR, IMCR, ADPT, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
ATYR aTyr Pharma	0.01	7.79	7.79
IMCR Immunocore	1.03	6.36	6.31
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ATYR aTyr Pharma	61.72%
IMCR Immunocore	84.50%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ATYR aTyr Pharma	3.70%
IMCR Immunocore	10.40%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

ATYR, IMCR, ADPT, and SRPT Headlines

Recent News About These Companies

Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges

2 hours ago | tipranks.com

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight

August 6 at 12:39 AM | gurufocus.com

Sarepta rises on strong quarterly earnings and revenue

August 6 at 10:09 PM | msn.com

Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say

August 6 at 8:01 PM | zacks.com

Sarepta Therapeutics: Hold Rating Amid Financial Gains and Clinical Uncertainties

August 6 at 7:39 PM | tipranks.com

Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates

August 6 at 6:45 PM | zacks.com

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing ...

August 6 at 6:13 PM | gurufocus.com

Sarepta Therapeutics (SRPT) Surges on Strong Q2 Earnings

August 6 at 6:13 PM | gurufocus.com

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

August 6 at 5:56 PM | globenewswire.com

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...

August 6 at 5:13 PM | gurufocus.com

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate ...

August 6 at 5:12 PM | gurufocus.com

Sarepta reportedly hired Trump-linked lobbying firm after gene therapy deaths

August 6 at 5:08 PM | msn.com

Sarepta Therapeutics (SRPT) Faces Regulatory and Financial Challenges

August 6 at 4:13 PM | gurufocus.com

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

August 6 at 4:05 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 6 at 10:00 AM | prnewswire.com

Raiffeisen Bank International AG Purchases 16,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

August 6 at 5:07 AM | marketbeat.com

SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

August 5 at 7:26 PM | globenewswire.com

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion

August 5 at 6:00 PM | globenewswire.com

Levi & Korsinsky Notifies Shareholders of Sarepta Therapeutics, Inc.(SRPT) of a Class Action Lawsuit and an Upcoming Deadline

August 5 at 4:10 PM | globenewswire.com

What to Expect from Sarepta Therapeutics's Earnings

August 5 at 3:20 PM | benzinga.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky

August 5 at 8:45 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, IMCR, ADPT, and SRPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.69 +0.64 (+5.79%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$11.80 +0.11 (+0.94%)

As of 08:00 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

aTyr Pharma NASDAQ:ATYR

$5.34 +0.12 (+2.30%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$5.34 0.00 (0.00%)

As of 08:30 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Immunocore NASDAQ:IMCR

$32.10 -0.40 (-1.23%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$23.17 -8.93 (-27.82%)

As of 07:00 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Sarepta Therapeutics NASDAQ:SRPT

$16.26 -0.49 (-2.93%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$17.59 +1.33 (+8.18%)

As of 08:32 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time